Clinical Trial Detail

NCT ID NCT01108055
Title Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stanford University
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Paclitaxel + Pazopanib

Age Groups: adult

No variant requirements are available.